Latest news with #Neuland
Associated Press
11 hours ago
- Health
- Associated Press
ZAP Surgical Announces First ZAP-X Gyroscopic Radiosurgery Patient Treatments in Latin America
SAN CARLOS, Calif.--(BUSINESS WIRE)--Jun 19, 2025-- ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced the first patient treatments using its ZAP-X® Gyroscopic Radiosurgery® platform in Latin America. Located in Neuland, Boquerón, Paraguay, Radioterapia Concordia ( ) has officially commenced clinical use, marking a major milestone in the decentralization of state-of-the-art brain tumor care across the region. This press release features multimedia. View the full release here: The ZAP-X® Gyroscopic Radiosurgery® platform at Radioterapia Concordia, Neuland, Boquerón, Paraguay In its first day of operation, four patients received next-generation stereotactic radiosurgery (SRS) with ZAP-X® for a range of intracranial conditions, including meningioma, acoustic neuroma, trigeminal neuralgia, and arteriovenous malformation (AVM). Historically, patients in the central regions of Latin America have had limited or no access to modern SRS, often requiring travel to large metropolitan hubs like Buenos Aires, São Paulo, or Santiago. Radioterapia Concordia now offers these advanced treatments locally, helping bridge a longstanding healthcare gap for rural communities. 'People in rural areas deserve to receive world-class medical care where they live, from people they understand, and at a fair price,' said Prof. Dr. Peter Douglas Klassen, Founder of Saludconcordia SA. 'With ZAP-X, we are bringing the most advanced SRS capabilities to communities that have long been underserved.' The creation of Radioterapia Concordia is further bolstered by its strategic location along the Bi-Oceanic Corridor—a transformative infrastructure project linking Brazil, Paraguay, Argentina, and Chile to improve regional access and trade. The new cancer center also benefits from its collaborative relationship with ZAP-X Zentrum Lingen in Germany, home to Europe's first ZAP-X system. 'This is more than just a technology deployment—it's a movement toward cooperative medicine,' said MBA MSc Edelgard Loewen, Case Manager at ZAP-X Zentrum Lingen. 'We're witnessing a new model emerge in Latin America—one that rises above the limitations of national and purely private healthcare systems to prioritize patients through altruistic, turnkey cancer care.' As an alternative to open brain surgery, stereotactic radiosurgery is a non-invasive, outpatient procedure used to treat many primary and metastatic brain tumors, as well as other disorders of the head and neck. Unlike traditional surgery however, SRS does not require incisions or anesthesia, and patients often return to normal activities the same day. The ZAP-X system is renowned for its unique gyroscopic design, which enables the delivery of radiosurgical beams from thousands of unique angles. This approach enhances the ability to concentrate radiation precisely on the tumor while minimizing dose to surrounding healthy brain tissue—an important factor in preserving cognitive function. ZAP-X is also the first and only vault-free SRS system, removing the need for costly shielded treatment rooms. Additionally, by utilizing a modern linear accelerator, ZAP-X eliminates the use of Cobalt-60, avoiding the exorbitant costs and regulatory burdens tied to radioactive isotopes. For more information about ZAP Surgical and the ZAP-X system, visit About ZAP Surgical Systems, Inc. ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® Gyroscopic Radiosurgery® platform. ZAP was founded in 2014 by Dr. John R. Adler, Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. Dr. Adler is also renowned as the inventor of the CyberKnife ® system and founder of Accuray, Inc. The ZAP-X platform incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. ZAP-X also utilizes a modern linear accelerator to eliminate legacy use of Cobalt-60. Learn more at ZAP Surgical and follow us on LinkedIn. View source version on CONTACT: Mark Arnold, ZAP Surgical Systems, Inc. Senior Vice President, Marketing +1 650 492 7797, ext. 101 Email:[email protected] KEYWORD: LATIN AMERICA NORTH AMERICA UNITED STATES PARAGUAY SOUTH AMERICA CALIFORNIA INDUSTRY KEYWORD: NEUROLOGY RADIOLOGY SURGERY ONCOLOGY HEALTH MEDICAL DEVICES HOSPITALS OTHER HEALTH SOURCE: ZAP Surgical Systems, Inc. Copyright Business Wire 2025. PUB: 06/19/2025 07:15 AM/DISC: 06/19/2025 07:15 AM
Economic Times
17-05-2025
- Business
- Economic Times
Will Neuland Laboratories recover after a 7% stock drop and plummeting profits?
The stock, which slumped as much as 11% during the session, closed at Rs 11,040. Last week, Neuland shares fell nearly 13%. Synopsis Neuland Laboratories' shares plunged, extending losses due to investor concerns over a 59% drop in Q4 profit, despite strong guidance. Increased operating costs and reduced sales volumes triggered the decline. While the company anticipates better growth in FY26, peers have reported stronger results and promising outlooks, further impacting investor sentiment. MUMBAI: Neuland Laboratories, one of the Dalal Street favourites in the recent bull run, tumbled almost 7% on Friday, extending losses to the third straight session, as the company's strong guidance failed to douse investor concerns over the 59% drop in its profit after tax in the fourth quarter. ADVERTISEMENT 'The increase in operating costs and reduced sales volumes led to Neuland shares falling today,' said Prathamesh Masdekar, research analyst, Stoxbox. ' The concern about operating costs has been ongoing since the last two quarters.' Masdekar said that while the company guided for better growth in FY26, the company's peers have reported better results and promising guidance as stock, which slumped as much as 11% during the session, closed at Rs 11,040. Last week, Neuland shares fell nearly 13%. (You can now subscribe to our ETMarkets WhatsApp channel) Why gold prices could surpass $4,000: JP Morgan's bullish outlook explained Why gold prices could surpass $4,000: JP Morgan's bullish outlook explained Cyient shares fall over 9% after Q4 profit declines, core business underperforms Cyient shares fall over 9% after Q4 profit declines, core business underperforms L&T Technology Services shares slide 7% after Q4 profit dips L&T Technology Services shares slide 7% after Q4 profit dips Trump-Powell standoff puts U.S. Rate policy in crosshairs: Who will blink first? Trump-Powell standoff puts U.S. Rate policy in crosshairs: Who will blink first? SEBI warns of securities market frauds via YouTube, Facebook, X and more SEBI warns of securities market frauds via YouTube, Facebook, X and more API Trading for All: Pi42 CTO Satish Mishra on How Pi42 is Empowering Retail Traders API Trading for All: Pi42 CTO Satish Mishra on How Pi42 is Empowering Retail Traders Security, transparency, and innovation: What sets Pi42 apart in crypto trading Security, transparency, and innovation: What sets Pi42 apart in crypto trading Bitcoin, Ethereum, or Altcoins? How investors are structuring their crypto portfolios, Avinash Shekhar explains Bitcoin, Ethereum, or Altcoins? How investors are structuring their crypto portfolios, Avinash Shekhar explains The rise of Crypto Futures in India: Leverage, tax efficiency, and market maturity, Avinash Shekhar of Pi42 explains The rise of Crypto Futures in India: Leverage, tax efficiency, and market maturity, Avinash Shekhar of Pi42 explains How Pi42 is simplifying crypto trading: CTO Satish Mishra on integrating technical & fundamental insights NEXT STORY
Time of India
17-05-2025
- Business
- Time of India
Will Neuland Laboratories recover after a 7% stock drop and plummeting profits?
MUMBAI: Neuland Laboratories , one of the Dalal Street favourites in the recent bull run, tumbled almost 7% on Friday, extending losses to the third straight session, as the company's strong guidance failed to douse investor concerns over the 59% drop in its profit after tax in the fourth quarter. 'The increase in operating costs and reduced sales volumes led to Neuland shares falling today,' said Prathamesh Masdekar, research analyst, Stoxbox. ' The concern about operating costs has been ongoing since the last two quarters.' Masdekar said that while the company guided for better growth in FY26, the company's peers have reported better results and promising guidance as well. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas For Sale in Dubai Might Surprise You Villas In Dubai | Search Ads Get Quote Undo The stock, which slumped as much as 11% during the session, closed at Rs 11,040. Last week, Neuland shares fell nearly 13%.
Business Standard
16-05-2025
- Business
- Business Standard
Neuland Labs drops after Q4 PAT slumps 59% YoY to Rs 28 cr
Neuland Laboratories declined 5.89% to Rs 11,171.10 after the company's consolidated net profit tumbled 58.8% to Rs 27.81 crore on 14.7% fall in revenue from operations to Rs 328.36 crore in Q4 FY25 over Q4 FY24. On quarter on quarter (QoQ) basis, the company's net profit declined 72.63% while revenue fell 17.5% in Q4 FY25. Profit before tax (PBT) dropped 57.4% YoY and 69.24% QoQ to Rs 39.30 crore in Q4 FY25. During the quarter EBITDA stood at Rs 58.2 crore, registering de-growth of 48.1% compared with Rs 112.2 crore posted in the same quarter last year. EBITDA margin reduced 1,140 bps to 17.3% in Q4 FY25 as against 28.7% in Q4 FY24. Total expenses fell 0.55% to Rs 296.52 crore in Q4 FY25 as compared with Rs 298.16 crore in Q4 FY24. Cost of material consumed stood at Rs 141.24 crore (down 19.28% Yoy), employee benefit expenses were at Rs 66.45 crore (down 6.35% YoY), finance cost stood at Rs 2.34 crore (down 35% YoY), while manufacturing expenses stood at Rs 45.09 crore (up 3.09% YoY ) during the period under review. On full year basis, the companys consolidated net profit declined 13.3% to Rs 260.11 crore on 5.2% fall in revenue from operations to Rs 1,476.84 crore in FY25 over FY24. Sucheth Davuluri, vice-chairman and chief executive officer of the company said, We saw marginal decrease in topline in FY25 as compared to FY24, which is further reflected in terms of the decline in operating margins. Nevertheless, these results are in line with our initial outlook at the start of the year regarding our expectations for FY25. During the course of the year we have committed to making investments which will significantly drive our growth in the medium and long term. Neuland continues to be recognized for its capabilities and quality track record, and we have good visibility on short and long term growth. Saharsh Davuluri, vice chairman and managing director, Neuland Laboratories added, The CMS revenues of Rs 637 crore were largely driven by molecules in the commercial segment. Even though the revenues have declined this year, we continue to see good traction in business from a wider range of customers Our peptide investment plan is on track. We continue to garner more projects in this space which further validates our excitement about the opportunities that the segment holds. At an overall level, we have molecules in our portfolio which are currently at the take off stage, therefore we expect our growth trajectory to resume in FY26. Meanwhile, the companys board recommended payment of final dividend of Rs 12 per share on a face value of Rs 10 each, for the financial year 2024-25. The dividend will be paid on or after five days from the date of declaration of the final dividend by the shareholders at the 41st Annual General Meeting (AGM). The company has fixed the record date as 18 July 2025. The companys board has approved the convening of the 41st AGM of the shareholders on Wednesday, July 30, 2025. Neuland Laboratories is a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates, and custom manufacturing solutions to customers in approximately 80 countries.
